1 / 25

Drugs for parkinsonism and dementia

Drugs for parkinsonism and dementia. Parkinsonism: summary. Diverse causes. Variable natural history. Main features: Bradykinesia Rigidity Coarse tremor Festinating gait. Aims of treatment. Prolong life Parkinsonism ultimately kills (often through respiratory infection).

hedda
Télécharger la présentation

Drugs for parkinsonism and dementia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drugs for parkinsonism and dementia

  2. Parkinsonism: summary • Diverse causes. • Variable natural history. • Main features: • Bradykinesia • Rigidity • Coarse tremor • Festinating gait

  3. Aims of treatment • Prolong life • Parkinsonism ultimately kills (often through respiratory infection). • No drug has yet been shown to affect mortality. • Restore function for as long as possible

  4. Dopaminergic neurone Receptors

  5. Idiopathic Parkinsonism: too little dopamine

  6. Drug-induced Parkinsonism: presence of antagonist (e.g. neuroleptic drugs)

  7. Promote dopamine D’amine precursor Direct agonists  metabolism Commonly used for idiopathic P Oppose acetyl choline Direct antagonists Mainly for drug-induced disease Strategies, in a nutshell

  8. Dopaminergic drugs • Direct agonists: ropinirole etc. • Levodopa • Enzyme inhibitors: • MAO-B inhibitors: selegiline. • COMT inhibitors: entacopone • Other drugs

  9. Dopamine agonists • Ropinirole • Pergolide • Cabergoline • Bromocryptine • Lisuride Ergot derivatives Ergot is a fungus that makes several vasoactive amines like ergotamine

  10. Dopamine agonists: adverse effects • GI upset • Neuropsychiatric – confusion and hallucinations • ERGOT DERIVATIVES: Fibrotic reactions: pulomonary, pericardial and retroperitoneal fibrosis. Uncommon.

  11. Dopamine agonists: clinical use • Ropinirole may be treatment of choice for younger patients. • Small starting dose, small dose increments, withdraw slowly. • May be used with levodopa in advanced cases.

  12. Levodopa • Dopamine does not cross the BBB • L-dihydroxy-phenyl-alanine (Levodopa; L-DOPA) is a precursor. • Levodopa does cross the BBB. • BUT…….

  13. Metabolised to dopamine: GOOD L-DOPA Metabolised to dopamine: BAD

  14. Enzyme inhibitor X Dopamine: GOOD Dopamine: BAD

  15. Levodopa + carbidopa • Levodopa crosses BBB and  dopamine • Carbidopa does not cross BBB. • Carbidopa inhibits peripheral production of dopamine.

  16. Levodopa pharmacokinetics • Absorbed by a ‘facilitated carrier’ mechanism. • Amino acids compete for transport. • Bioavailability reduced after meals. • Extensive first pass. • Short half life.

  17. Levodopa adverse effects • GI upset • Dyskinesias (choreo-athetosis, facial tics, dystonia and others). • Erratic response – probably related to rapid changes in dopamine delivery. ‘On-off phenomenon’. • Cardiovascular: postural hpyotension is common. (Paradoxically) levodopa may worsen hypertension.

  18. Levodopa: clinical use. • Probably still among first-line choices, especially for older patients. • May be added to dopamine agonists for advanced disease. • More adverse effects than dopamine agonists. • Small starting dose and small dose increments. • Intervals between doses may need to be short in some patients.

  19. Monoamine-oxidase inhibitors • MAO-A inhibitors – relevant to depression. • MAO-B inhibitors – e.g. selegiline. • MAO-B metabolises dopamine. • Selegiline is used with levodopa to reduce ‘end-of-dose’ problems. • GREAT CAUTION if there is postural hypotension

  20. Catechol-o-methyltransferase inhibitors • COMT metabolises levodopa. • Entacapone and tolcapone inhibit COMT. • COMT inhibition peripherally increases available Levodopa for the brain. • COMT inhibition in the brain ‘diverts’ levodopa towards dopamine. • Used as an adjunct to levodopa. • GI upset; rarely hepatitis.

  21. Drugs for dementia

  22. NICE guidelines • Alzheimers should be diagnosed by a specialist unit. • Treatment should be started by specialists. • Assessment 2-4 months after maintenance dose established. • Reassessment every 6-months in specialist unit.

  23. Basic pharmacodynamics. • Loss of neuronal function. • All the drugs are cholinesterase inhibitors, and merely potentiate this one transmitter. • This is a pretty CRUDE approach to treatment. • But it can achieve modest improvement in cognition

  24. Acetylcholinesterase • An enzyme of the synaptic cleft. • Terminates acetyl-choline. • Anticholinesterases are traditionally used for: • Reversal of depolarising muscle relaxants in GA. • Management of myasthenia gravis. • E.g. Neostigmine, pyridostigmine etc.

  25. Anticholinesterases for Alzheimers • Donepezil, galantamine, memantine, rivastigmine. • The ‘traditional’ drugs gain negligible entry to the CNS (they are mainly needed peripherally). • Anticholinesterases potentiate acetylcholine in the periphery, e.g.: • Bradycardia • Increased gastric secretion - ulcer

More Related